Genocea Biosciences, Inc. (GNCA)
GNCAPrice: $0
Fair Value: 🔒
🔒score
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation s... more
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunoth... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | William Clark |
| IPO Date | 2014-02-05 | CAGR | -0.01% |
| Employees | 74 | Website | www.genocea.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
GNCA chart loading...
Fundamentals
Technicals
| Enterprise Value | $84.25M | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | — |
| P/CF Ratio | — | P/FCF Ratio | — |
| EPS | — | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | 1% |
| Operating Margin | -31.74% | Profit Margin | -9.4% |
| ROE | -0.86% | ROA | -0.28% |
| ROCE | -1.4% | Current Ratio | 2.24 |
| Quick Ratio | 2.24 | Cash Ratio | 1.99 |
| Debt/Equity | 0.41 | Interest Coverage | 46.47 |
| Altman Z Score | — | Piotroski Score | — |